All Issue

2026 Vol.56, Issue 2 Preview Page

Review Article

Molecular insights into Hepatitis C virus: Evolution, Pathogenesis, and Antiviral Therapies
Garima Singh1
,
Madhavi Singh1
,
Ananya Singh1
,
Neelam Yadav2
,
Sarika Yadav3
,
Lata Israni Shukla4
,
Dinesh Kumar Yadav1*
1Molecular Biology and Genetic Engineering Laboratory, Department of Botany, University of Allahabad, Prayagraj-211002, India
2Ewing Christian College, University of Allahabad, Prayagraj-211003, India
3Department of Biochemistry, Sri Venkateswara College, University of Delhi, New Delhi-110021, India
4Department of Biotechnology, School of Life Sciences, Pondicherry University, Kalapet, Puducherry-605014, India
*dky@allduniv.ac.in
10 August 2026. pp. 84-111
PDF XML Citation
Abstract

Globally, an estimated 50 million individuals are chronically infected with the Hepatitis C virus (HCV), with approximately one million new infections occurring annually. According to the 2024 WHO report, 242,000 deaths from HCV-related liver diseases, including cirrhosis and hepatocellular carcinoma (HCC), were recorded in 2022. The virus demonstrates striking geographic heterogeneity in prevalence and possesses a complex and intriguing phylogenetic history. In line with the global hepatitis eradication strategy, the WHO has set ambitious targets of reducing new HCV infections by 90% and HCV-related mortality by 65% by 2030. Direct-acting antiviral (DAA) therapies, which target critical viral proteins and host-pathogen interactions, have revolutionized treatment by achieving sustained virologic response (SVR) rates exceeding 95%. Nevertheless, resistance- associated substitutions (RASs) and high cost of therapy remain significant barriers to universal access, particularly in low– and middle-income countries. These limitations underscore the urgent need for effective prophylactic vaccines that provide broad immunoprotection across the diverse HCV genotypes. This multidimensional review synthesizes current knowledge on the molecular and phylogenetic evolution of HCV, highlighting genotype-specific features that contribute to viral persistence and pathogenesis. Furthermore, it examines therapeutic advances, challenges in antiviral defense, and emerging candidate molecules for vaccine development. By integrating molecular insights with an evolutionary perspective, this review aims to provide a comprehensive framework for understanding HCV biology and suggesting future strategies towards global eradication.

Keywords
Direct-acting antiviral agents
Hepatocellular carcinoma
Hepatitis C Virus
Liver cirrhosis
References
1

Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081-1088.

10.1016/S0140-6736(16)30579-727394647PMC5100695
2

Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: A Community-Based Long-Term Prospective Study. J Infect Dis. 2012;206(4): 469-477.

10.1093/infdis/jis385
3

Geddawy A, Ibrahim YF, Elbahie NM, Ibrahim MA. Direct-Acting Anti-Hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction. J Transl Intern Med. 2017;5(1):8-17.

10.1515/jtim-2017-000728680834PMC5490957
4

Tsukiyama-Kohara K, Iizuka N, Kohara M, Nomoto A. Internal ribosome entry site within hepatitis C virus RNA. J Virol. 1992;66(3):1476-1483.

10.1128/jvi.66.3.1476-1483.19921310759PMC240872
5

Tanaka T, Kato N, Cho MJ, Sugiyama K, Shimotohno K. Structure of the 3′terminus of the hepatitis C virus genome. J Virol. 1996;70(5):3307-3312.

10.1128/jvi.70.5.3307-3312.19968627816PMC190199
6

Shi G, Suzuki T. Molecular Basis of Encapsidation of Hepatitis C Virus Genome. Front Microbiol. 2018;9:396.

10.3389/fmicb.2018.0039629563905PMC5845887
7

McLauchlan J. Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes. J Viral Hepat. 2000;7(1):2-14.

10.1046/j.1365-2893.2000.00201.x
8

Kountouras J, Zavos C, Chatzopoulos D. Apoptosis in hepatitis C. J Viral Hepat. 2003;10(5):335-342.

10.1046/j.1365-2893.2003.00452.x
9

Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med. 2003;197(5):633-642.

10.1084/jem.2002175612615904PMC2193821
10

Cocquerel L, Meunier JC, Pillez A, Wychowski C, Dubuisson J. A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2. J Virol. 1998;72(3):2183-91.

10.1128/JVI.72.3.2183-2191.1998
11

Cocquerel L, Wychowski C, Minner F, Penin F, Dubuisson J. Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins. J Virol. 2000;74(8):3623-33.

10.1128/JVI.74.8.3623-3633.2000
12

Op De Beeck A, Montserret R, Duvet S, Cocquerel L, Cacan R, Barberot B, et al. The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization. J Biol Chem. 2000; 275(40):31428-31437.

10.1074/jbc.M003003200
13

Meunier JC, Fournillier A, Choukhi A, Cahour A, Cocquerel L, Dubuisson J, et al. Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex. J Gen Virol. 1999;80(4):887-896.

10.1099/0022-1317-80-4-887
14

Roccasecca R, Ansuini H, Vitelli A, Meola A, Scarselli E, Acali S, et al. Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol. 2003;77(3):1856-67.

10.1128/JVI.77.3.1856-1867.200312525620PMC140892
15

Penin F, Combet C, Germanidis G, Frainais PO, Deléage G, Pawlotsky JM. Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol. 2001;75(12):5703-10.

10.1128/JVI.75.12.5703-5710.200111356980PMC114285
16

Carrère-Kremer S, Montpellier-Pala C, Cocquerel L, Wychowski C, Penin F, Dubuisson J. Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. J Virol. 2002;76(8):3720-3730.

10.1128/JVI.76.8.3720-3730.200211907211PMC136108
17

Gonzalez ME, Carrasco L. Viroporins. FEBS Lett. 2003;552(1):28-34.

10.1016/S0014-5793(03)00780-4
18

Sakai A, Claire MS, Faulk K, Govindarajan S, Emerson SU, Purcell RH, et al. The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc. Natl. Acad. Sci. U.S.A. 2003;100(20):11646-51.

10.1073/pnas.183454510014504405PMC208812
19

Yamaga AK, Ou JH. Membrane topology of the hepatitis C virus NS2 protein. J Biol Chem. 2002;277(36):33228-34.

10.1074/jbc.M202304200
20

Hijikata M, Shimizu YK, Kato H, Iwamoto A, Shih JW, Alter HJ, et al. Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol. 1993;67(4):1953-58.

10.1128/jvi.67.4.1953-1958.19938383220PMC240263
21

Santolini E, Pacini L, Fipaldini C, Migliaccio G, La Monica N. The NS2 protein of hepatitis C virus is a transmembrane polypeptide. J Virol. 1995;69(12):7461-7471.

10.1128/jvi.69.12.7461-7471.19957494252PMC189684
22

Jirasko V, Montserret R, Lee JY, Gouttenoire J, Moradpour D, Penin F, et al. Structural and functional studies of nonstructural protein 2 of the hepatitis C virus reveal its key role as organizer of virion assembly. PLoS Pathog. 2010;6(12):e1001233.

10.1371/journal.ppat.100123321187906PMC3002993
23

Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. A second hepatitis C virus-encoded proteinase. Proc. Natl. Acad. Sci. U.S.A. 1993;90(22):10583-87.

10.1073/pnas.90.22.105838248148PMC47821
24

Gwack Y, Kim DW, Han JH, Choe J. DNA helicase activity of the hepatitis C virus nonstructural protein 3. Eur. J. Biochem. 1997;250(1):47-54.

10.1111/j.1432-1033.1997.00047.x
25

Hügle T, Fehrmann F, Bieck E, Kohara M, Kräusslich HG, Rice CM, et al. The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane protein. Virol. 2001;284(1):70-81.

10.1006/viro.2001.0873
26

Lundin M, Monné M, Widell A, Von Heijne G, Persson MA. Topology of the membrane-associated hepatitis C virus protein NS4B. J Virol. 2003;77(9):5428-38.

10.1128/JVI.77.9.5428-5438.200312692244PMC153960
27

Kato J, Kato N, Yoshida H, Ono-Nita SK, Shiratori Y, Omata M. Hepatitis C virus NS4A and NS4B proteins suppress translation in vivo. J Med Virol. 2002;66(2):187-99.

10.1002/jmv.2129
28

Piccininni S, Varaklioti A, Nardelli M, Dave B, Raney KD, McCarthy JE. Modulation of the hepatitis C virus RNA-dependent RNA polymerase activity by the non-structural (NS) 3 helicase and the NS4B membrane protein. J Biol Chem. 2002;277(47):45670-79.

10.1074/jbc.M204124200
29

Ivashkina N, Wölk B, Lohmann V, Bartenschlager R, Blum HE, Penin F, et al. The hepatitis C virus RNA-dependent RNA polymerase membrane insertion sequence is a transmembrane segment. J Virol. 2002;76(24):13088-93.

10.1128/JVI.76.24.13088-13093.200212438637PMC136709
30

Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL, Mathieu M, et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A.1999;96(23):13034-13039.

10.1073/pnas.96.23.1303410557268PMC23895
31

Ago H, Adachi T, Yoshida A, Yamamoto M, Habuka N, Yatsunami K, et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure. 1999;7(11):1417-1426.

10.1016/S0969-2126(00)80031-3
32

Leesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol. 1999;6(10):937-943.

33

Elbrolosy AM, Elhamouly MS, Eed EM, El Gedawy GA, Abozeid M, Elabd NS. Hepatitis C core antigen: a simple predictive marker for treatment response to the new direct-acting antiviral drugs in chronic HCV Egyptian patients. Egypt. Liver. J. 2021;11:19.

10.1186/s43066-021-00092-w
34

Nawaz A, Manzoor A, Ahmed S, Ahmed N, Abbas W, Mir MA, et al. Therapeutic approaches for chronic hepatitis C: a concise review. Front. Pharmacol. 2024;14:1334160.

10.3389/fphar.2023.133416038283838PMC10811011
35

Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, Bourne N, et al. Multiple Effects of Silymarin on the Hepatitis C Virus Lifecycle. Hepatol. 2010;51(6):1912-21.

10.1002/hep.2358720512985PMC2909978
36

Drane D, Maraskovsky E, Gibson R, Mitchell S, Barnden M, Moskwa A, et al. Priming of CD4+ and CD8+ T-cell responses using a HCV core ISCOMATRIXTM vaccine: A phase I study in healthy volunteers. Human Vaccines, 2009;5(3): 151-157.

10.4161/hv.5.3.6614
37

Patra T, Meyer K, Haga Y, Reagan EK, Weissman D, Ray R. Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity. npj Vaccines. 2023;8:42.

10.1038/s41541-023-00635-936934116PMC10024013
38

Balakrishnan P, Saravanan S, Vignesh R, Sivamalar S, Nallusamy D, Sankar S, et al. Discovery of HCV vaccine: Where do we stand? Indian J. Med. Microbiol. 2025;57:100940.

10.1016/j.ijmmb.2025.100940
39

Wei S, Hu X, Du L, Zhao L, Xue H, Liu C, et al. Inhibitor Development against p7 Channel in Hepatitis C Virus. Molecules. 2021;26(5):1350.

10.3390/molecules2605135033802584PMC7961618
40

Bachmetov L, Gal‐Tanamy M, Shapira A, Vorobeychik M, Giterman‐Galam T, Sathiyamoorthy P, et al. Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity. J Viral Hepat. 2012;19(2):e81-e88.

10.1111/j.1365-2893.2011.01507.x
41

Weiland O, Ahlén G, Diepolder H, Jung MC, Levander S, Fons M, et al. Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C. Mol. Ther. 2013;21(9):1796-1805.

10.1038/mt.2013.11923752314PMC3776630
42

Einav S, Sobol HD, Gehrig E, Glenn JS. The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. J. Infect. Dis. 2010;202(1):65-74.

10.1086/65308020486856PMC3008401
43

Graci JD, Jung SP, Pichardo J, Lahser F, Tong X, Gu Z, et al. PTC725, an NS4B-Targeting Compound, Inhibits a Hepatitis C Virus Genotype 3 Replicon, as Predicted by Genome Sequence Analysis and Determined Experimentally. Antimicrob. Agent. Chemother. 2016;60(12):7060-7066.

10.1128/AAC.01272-1627620477PMC5118984
44

Zhang N, Turpoff A, Zhang X, Huang S, Liu Y, Almstead N, et al. Discovery of 2-(4-sulfonamidophenyl)-indole 3-carboxamides as potent and selective inhibitors with broad hepatitis C virus genotype activity targeting HCV NS4B. Bioorg. Med. Chem. Lett. 2016;26(2):594-601.

10.1016/j.bmcl.2015.11.065
45

Zakaryan H, Arabyan E, Oo A, Zandi K, Zandi K. Flavonoids: promising natural compounds against viral infections. Arch. Virol. 2017;162:2539-2551.

10.1007/s00705-017-3417-y28547385PMC7087220
46

Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem. 2003;278(43): 41624-30.

10.1074/jbc.M305289200
47

Yamamoto H, Collier M, Loerke J, Ismer J, Schmidt A, Hilal T, et al. Molecular architecture of the ribosome-bound Hepatitis C Virus internal ribosomal entry site RNA. EMBO J. 2015;34(24):3042-3058.

10.15252/embj.20159246926604301PMC4687786
48

Scott S, Li Y, Bermek O, Griffith JD, Lemon SM, Choi KH. Binding of microRNA-122 to the hepatitis C virus 5′ untranslated region modifies interactions with poly (C) binding protein 2 and the NS5B viral polymerase. Nucleic Acids Res. 2023;51(22):12397-12413.

10.1093/nar/gkad100037941151PMC10711565
49

Panigrahi M, Palmer MA, Wilson JA. MicroRNA-122 Regulation of HCV Infections: Insights from Studies of miR-122-Independent Replication. Pathogens. 2022;11(9):1005.

10.3390/pathogens1109100536145436PMC9504723
50

Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006; 3(2):47-52.

10.7150/ijms.3.4716614742PMC1415841
51

Pol S, Parlati L, Jadoul M. Hepatitis C virus and the kidney. Nat Rev Nephrol. 2019;15(2):73-86.

10.1038/s41581-018-0081-8
52

Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterol. 2015;149(6):1345-1360.

10.1053/j.gastro.2015.08.035
53

Pozzato G, Mazzaro C, Dal Maso L, Mauro E, Zorat F, Moratelli G, et al. Hepatitis C virus and non-Hodgkin’s lymphomas: meta-analysis of epidemiology data and therapy options. World J Hepatol. 2016; 8(2):107-16.

10.4254/wjh.v8.i2.10726807206PMC4716526
54

Stapleton JT, Foung S, Muerhoff AS, Bukh J, Simmonds P. The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae. J Gen Virol. 2011;92(Pt 2):233-246.

10.1099/vir.0.027490-021084497PMC3081076
55

Lauck M, Sibley SD, Lara J, Purdy MA, Khudyakov Y, Hyeroba D, et al. A novel hepacivirus with an unusually long and intrinsically disordered NS5A protein in a wild Old-World primate. J Virol. 2013;87(16):8971-8981.

10.1128/JVI.00888-1323740998PMC3754081
56

Simmonds P. The origin of hepatitis C virus. Curr Top Microbiol Immunol. 2013;369:1-15.

10.1007/978-3-642-27340-7_1
57

Zhao L, Feng Y, Xia XS. The different epidemic and evolution of HCV genotypes. Yi Chuan, 2012;34:666-672.

10.3724/SP.J.1005.2012.00666
58

Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-176.

59

Guntipalli P, Pakala R, Kumari Gara S, Ahmed F, Bhatnagar A, Endaya Coronel MK, et al. Worldwide prevalence, genotype distribution and management of hepatitis C. Acta Gastroenterol Belg. 2021;84(4):637-656.

10.51821/84.4.015
60

Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824-40.

10.3748/wjg.v22.i34.782427678366PMC5016383
61

Mbisa JL, Lapp Z, Bibby DF, Phillips LT, Manso CF, Packer S, et al. Identification of 2 Novel Subtypes of Hepatitis C Virus Genotype 8 and a Potential New Genotype Successfully Treated with Direct Acting Antivirals. J Infect Dis. 2024;230(6):e1254-e1262.

10.1093/infdis/jiae25338717937PMC11646602
62

Jackowiak P, Kuls K, Budzko L, Mania A, Figlerowicz M, Figlerowicz M. Phylogeny and molecular evolution of the hepatitis C virus. Infect Genet Evol. 2014;21:67-82.

10.1016/j.meegid.2013.10.021
63

Pang PS, Planet PJ, Glenn JS. The Evolution of the Major Hepatitis C Genotypes Correlates with Clinical Response to Interferon Therapy. PloS One. 2009;4(8):e6579.

10.1371/journal.pone.000657919668364PMC2719056
64

Kalinina O, Norder H, Mukomolov S, Magnius LO. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J Virol. 2002;76(8):4034-4043.

10.1128/JVI.76.8.4034-4043.200211907242PMC136067
65

Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59(1): 318-327.

10.1002/hep.2674424115039PMC4063340
66

Scheel TK, Galli A, Li YP, Mikkelsen LS, Gottwein JM, Bukh J. Productive homologous and non-homologous recombination of hepatitis C virus in cell culture. PLoS Pathog. 2013;9(3):e1003228.

10.1371/journal.ppat.100322823555245PMC3610614
67

Sallam M, Khalil R. Contemporary Insights into Hepatitis C Virus: A Comprehensive Review. Microorganisms. 2024;12(6):1035.

10.3390/microorganisms1206103538930417PMC11205832
68

Di Marco L, Cannova S, Ferrigno E, Landro G, Nonni R, Mantia CL, et al. A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs). Viruses. 2025;17(2):163.

10.3390/v1702016340006918PMC11860415
69

Hnatyszyn HJ. Chronic hepatitis C and genotyping: The clinical significance of determining HCV genotypes. Antivir. Ther. 2005;10(1): 1-11.

10.1177/135965350501000118
70

Alanazi A, Abdullah E. Epidemiological Assessment of Hepatitis C Virus Seroprevalence Among Screened Populations in Arar City, Northern Saudi Arabia. J Cult. Anal. Soc. Change. 2025;10 (4):5169-5175.

71

Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology. 1997;25(3):754-758.

10.1002/hep.510250344
72

Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Bréchot C. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med. 1995;122(3):161-168.

10.7326/0003-4819-122-3-199502010-00001
73

De Mitri MS, Poussin K, Baccarini P, Pontisso P, D'Errico A, Simon N, et al. HCV-associated liver cancer without cirrhosis. Lancet. 1995;345(8947):413-415.

10.1016/S0140-6736(95)90400-X
74

Féray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maertens G, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterol. 1995;108(4):1088-1096.

10.1016/0016-5085(95)90207-4
75

Ran X, Xu Y, Wang Y, Zeng C, Gong C, Wang N, et al. Genotype 3 is linked to worse liver disease progression in hepatitis C patients even after SVR following DAA therapy. Front. Cell. Infect. Microbiol. 2025;15:1510939.

10.3389/fcimb.2025.151093939963406PMC11830654
76

Probst A, Dang T, Bochud M, Egger M, Negro F, Bochud PY. Role of Hepatitis C virus genotype 3 in liver fibrosis progression - a systematic review and meta-analysis. J Viral Hepat. 2011;18(11):745-759.

10.1111/j.1365-2893.2011.01481.x
77

Indolfi G, Azzari C, Resti M. Polymorphisms in the IFNL3/IL28B gene and hepatitis C: from adults to children. World J Gastroenterol. 2014;20(28):9245-9252.

78

Randall G, Chen L, Panis M, Fischer AK, Lindenbach BD, Sun J, et al. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroentero. 2006;131(5):1584-1591.

10.1053/j.gastro.2006.08.043
79

Sakhaee F, Ghazanfari M, Vaziri F, Jamnani FR, Davari M, Gharibzadeh S, et al. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection. Infect. Genet. Evol. 2017 ;54:330-337.

10.1016/j.meegid.2017.07.023
80

Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of Acute Hepatitis C with Interferon Alfa-2b. N Engl J Med. 2001;345(20):1452-1457.

10.1056/NEJMoa011232
81

Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterol. 1994;107(3):812-817.

10.1016/0016-5085(94)90131-7
82

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection. N Engl J Med. 2002;347(13):975-982.

10.1056/NEJMoa020047
83

Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-Guided Telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365(11):1014-1024.

10.1056/NEJMoa101446321916639PMC3809077
84

Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-2416.

10.1056/NEJMoa1012912
85

Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts SK, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25), 2417-2428.

10.1056/NEJMoa1013086
86

Maasoumy B, Manns MP. Optimal treatment with boceprevir for chronic HCV infection. Liver Int. 2013;33(Suppl 1):14-22.

10.1111/liv.12070
87

Jesudian AB, Jacobson IM. Optimal treatment with telaprevir for chronic HCV infection. Liver Int. 2013;33(Suppl 1):3-13.

10.1111/liv.12079
88

Ruiz-Cobo JC, Llaneras J, Forns X, Gallego Moya A, Conde Amiel I, Arencibia A, et al. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir. Alimen. Pharmacol. Ther. 2024;60(2):201-211.

10.1111/apt.18020
89

Liu CH, Kao JH. Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5. Hepatol. Int. 2022;16:1001-1019.

10.1007/s12072-022-10390-z35876967PMC9309604
90

Fauvelle C, Lepiller Q, Felmlee DJ, Fofana I, Habersetzer F, Stoll-Keller F, et al. Hepatitis C virus vaccines— progress and perspectives. Microb. Pathog. 2013;58:66-72.

10.1016/j.micpath.2013.02.005
91

Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities. Expert Opin Ther Pat. 2012;22(4):391-415.

10.1517/13543776.2012.673589
92

Dahari H, Feinstone SM, Major ME. Meta-Analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterol. 2010;139(3):965-974.

10.1053/j.gastro.2010.05.07720621699PMC3075980
93

Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol. 2011;54(6):1273-1285.

10.1016/j.jhep.2010.09.040
94

Chmielewska AM, Naddeo M, Capone S, Ammendola V, Hu K, Meredith L, et al. Combined adenovirus vector and hepatitis C virus envelope protein Prime-Boost regimen elicits T-cell and neutralizing antibody immune responses. J Virol. 2014;88(10):5502-5510.

10.1128/JVI.03574-1324599994PMC4019094
95

Verma R, Khanna P, Chawla S. Hepatitis C vaccine: Need of the hour. Hu. Hum. Vaccines Immunother. 2014;10(7):1927-1929.

10.4161/hv.2903325424801PMC4186052
96

Garcia A, Fernández S, Toro F, De Sanctis JB. An overview of hepatitis C vaccines. Recent Pat Inflamm Allergy Drug Discov. 2014;8(2):85-91.

10.2174/1872213X08666140704115149
97

Stoll‐Keller F, Barth H, Fafi‐Kremer S, Zeisel MB, Baumert TF. Development of hepatitis C virus vaccines: challenges and progress. Expert Rev. Vaccines. 2009;8(3):333-345.

10.1586/14760584.8.3.33319249975PMC2966876
98

Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Mancip J, et al. A Prime-Boost strategy using Virus-Like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci. Transl. Med. 2011;3(94):94ra71.

10.1126/scitranslmed.3002330
99

Pishraft-Sabet L, Taheri T, Memarnejadian A, Mokhtari Azad T, Asgari F, Rahimnia R, et al. Immunogenicity of Multi-Epitope DNA and Peptide Vaccine Candidates Based on Core, E2, NS3 and NS5B HCV Epitopes in BALB/c Mice. Hepat. Mon. 2014;14(10):e22215.

10.5812/hepatmon.2221525419219PMC4238154
100

Kutikuppala LVS, Kourampi I, Kanagala RSD, Bhattacharjee P, Boppana SH. Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses. Med. Sci. 2024;12(2):28.

10.3390/medsci1202002838804384PMC11130901
Information
  • Publisher :The Korean Society for Microbiology and The Korean Society of Virology
  • Publisher(Ko) :대한미생물학회‧대한바이러스학회
  • Journal Title :JOURNAL OF BACTERIOLOGY AND VIROLOGY
  • Volume : 56
  • No :2
  • Pages :84-111
  • Received Date : 2026-06-02
  • Revised Date : 2026-07-01
  • Accepted Date : 2026-07-17
  • DOI :https://doi.org/10.4167/jbv.2026.56.2.084
Journal Informaiton JOURNAL OF BACTERIOLOGY AND VIROLOGY JOURNAL OF BACTERIOLOGY AND VIROLOGY
  • NRF
  • 임플란트학회 전용 배너
  • KOFST
  • crossref crossmark
  • crossref cited-by
  • crossref funder-registry
  • crosscheck
  • orcid
  • open access
  • ccl
Journal Informaiton Journal Informaiton - close